Consuelo Wilkins

, MD, MSCI

Professor of Medicine, Senior Vice President and Senior Associate Dean for Health Equity and Inclusive Excellence, Vanderbilt University Medical Center

Consuelo H. Wilkins, MD, MSCI, Professor of Medicine, is Senior Vice President and Senior Associate Dean for Health Equity and Inclusive Excellence, Vanderbilt University Medical Center. She is a nationally recognized thought leader in health equity and in addressing the elimination of systemic inequities that impact the health and well-being of minoritized racial and ethnic groups. Throughout her career, Dr. Wilkins has focused her research on racial and ethnic health disparities using a community engaged approach. She is currently Principal Investigator of three NIH-funded centers: the Southeast Collaborative for Innovative and Equitable Solutions to Chronic Disease Disparities, a collaboration between Vanderbilt, Miami, and Meharry (NIMHD); the Vanderbilt Clinical and Translational Science Award (NCATS); and a national Recruitment Innovation Center (NCATS), which is part of the Trial Innovation Network. She has published more than 100 peer-reviewed papers primarily on health equity and engagement.

Dr. Wilkins has received many national awards and honors. She is an elected member of the National Academy of Medicine and the American Society for Clinical Investigation.

Dr. Wilkins earned a Bachelor of Science in microbiology and Doctor of Medicine from Howard University. She completed a residency in Internal Medicine at Duke University Medical Center and a Geriatric Medicine fellowship at Washington University School of Medicine/Barnes-Jewish Hospital. Following her medical training, she earned a Master of Science in Clinical Investigation from Washington University School of Medicine.

Read more

This Speaker's Sessions

Panel
Tuesday Oct. 17
-
1:30–2:15 PM ET
Watch Replay
Now Live!

Achieving Equity in Alzheimer's Disease

As Alzheimer’s therapies continue to make great progress, questions remain about how we can ensure equitable access to the right treatments, for the right patients, at the right time. What do we know--and not know--about the etiology of the disease in and the impact of new treatments on minoritized, and especially Black, populations?  Key Question: How do we achieve success with such low rates of racial and ancestral diversity in clinical trials?

View SessionWatch Replay